Representative patch - clamp current measurements showing GR3027 antagonism of the 3α, 21 - dihydroxy - 5α - pregnan - 20 - one ( THDOC )- enhanced GABA modulation of α1β2γ2L and α5β3γ2L GABAA receptors and no inhibition of GABA. A: 1 μM GR3027 antagonism of 100 nM THDOC enhanced 30 μM GABA - mediated current response with the α1β2γ2L GABAA receptor. B: 1 μM GR3027 did not antagonize the 30 μM GABA response of the α1β2γ2L GABAA receptor. C: concentration response of the GR3027 antagonism of 100 nM THDOC enhanced 30 μM GABA - mediated current response with the α1β2γ2L GABAA receptor. D: 1 μM GR3027 antagonism of 200 nM THDOC enhanced 0. 3 μM GABA - mediated current response with the α5β3γ2L GABAA receptor. E: 1 μM GR3027 did not antagonize the 0. 3 μM GABA response of the α5β3γ2L GABAA receptor. F: concentration response of the GR3027 antagonism of 200 nM THDOC enhanced 0. 3 μM GABA - mediated current response with the α5β3γ2L GABAA receptors.	"GR3027	58	64	Chemical/Drug"	"α1β2γ2L	167	174	Gene/Protein"	"α5β3γ2L GABAA receptors	179	202	Gene/Protein"	"GR3027	238	244	Chemical/Drug"	"α1β2γ2L GABAA receptor	329	351	Gene/Protein"	"GR3027	361	367	Chemical/Drug"	"α1β2γ2L GABAA receptor	418	440	Gene/Protein"	"GR3027	475	481	Chemical/Drug"	"α1β2γ2L GABAA receptor	566	588	Gene/Protein"	"GR3027	598	604	Chemical/Drug"	"α5β3γ2L GABAA receptor	691	713	Gene/Protein"	"GR3027	723	729	Chemical/Drug"	"α5β3γ2L GABAA receptor	782	804	Gene/Protein"	"GR3027	839	845	Chemical/Drug"	"α5β3γ2L GABAA receptors	932	955	Gene/Protein"	"[{""token"": ""GR3027"", ""start_span"": 58, ""end_span"": 64, ""type"": ""Chemical/Drug""}, {""token"": ""\u03b11\u03b22\u03b32L"", ""start_span"": 167, ""end_span"": 174, ""type"": ""Gene/Protein""}, {""token"": ""\u03b15\u03b23\u03b32L GABAA receptors"", ""start_span"": 179, ""end_span"": 202, ""type"": ""Gene/Protein""}, {""token"": ""GR3027"", ""start_span"": 238, ""end_span"": 244, ""type"": ""Chemical/Drug""}, {""token"": ""\u03b11\u03b22\u03b32L GABAA receptor"", ""start_span"": 329, ""end_span"": 351, ""type"": ""Gene/Protein""}, {""token"": ""GR3027"", ""start_span"": 361, ""end_span"": 367, ""type"": ""Chemical/Drug""}, {""token"": ""\u03b11\u03b22\u03b32L GABAA receptor"", ""start_span"": 418, ""end_span"": 440, ""type"": ""Gene/Protein""}, {""token"": ""GR3027"", ""start_span"": 475, ""end_span"": 481, ""type"": ""Chemical/Drug""}, {""token"": ""\u03b11\u03b22\u03b32L GABAA receptor"", ""start_span"": 566, ""end_span"": 588, ""type"": ""Gene/Protein""}, {""token"": ""GR3027"", ""start_span"": 598, ""end_span"": 604, ""type"": ""Chemical/Drug""}, {""token"": ""\u03b15\u03b23\u03b32L GABAA receptor"", ""start_span"": 691, ""end_span"": 713, ""type"": ""Gene/Protein""}, {""token"": ""GR3027"", ""start_span"": 723, ""end_span"": 729, ""type"": ""Chemical/Drug""}, {""token"": ""\u03b15\u03b23\u03b32L GABAA receptor"", ""start_span"": 782, ""end_span"": 804, ""type"": ""Gene/Protein""}, {""token"": ""GR3027"", ""start_span"": 839, ""end_span"": 845, ""type"": ""Chemical/Drug""}, {""token"": ""\u03b15\u03b23\u03b32L GABAA receptors"", ""start_span"": 932, ""end_span"": 955, ""type"": ""Gene/Protein""}]"
As a result, Coprococcus and Marvinbryantia were represented in baboon enterotype 1, Turicibacter, Pedobacter and Vasilyevaea were represented in baboon enterotype 2, and Acinetobacter, Paenibacillus, Arthrobacter, Pectobacterium, Desemzia and Pseudomonas were represented in baboon enterotype 3, but these genera did not contribute significantly to the human enterotypes ( Tables 1. 2 and Supplementary Table 2 ).	"Coprococcus	13	24	Organism/Species"	"Marvinbryantia	29	43	Organism/Species"	"baboon	64	70	Organism/Species"	"Turicibacter	85	97	Organism/Species"	"Pedobacter	99	109	Organism/Species"	"Vasilyevaea	114	125	Organism/Species"	"baboon	146	152	Organism/Species"	"Acinetobacter	171	184	Organism/Species"	"Paenibacillus	186	199	Organism/Species"	"Arthrobacter	201	213	Organism/Species"	"Pectobacterium	215	229	Organism/Species"	"Desemzia	231	239	Organism/Species"	"Pseudomonas	244	255	Organism/Species"	"baboon	276	282	Organism/Species"	"human	354	359	Organism/Species"	"[{""token"": ""Coprococcus"", ""start_span"": 13, ""end_span"": 24, ""type"": ""Organism/Species""}, {""token"": ""Marvinbryantia"", ""start_span"": 29, ""end_span"": 43, ""type"": ""Organism/Species""}, {""token"": ""baboon"", ""start_span"": 64, ""end_span"": 70, ""type"": ""Organism/Species""}, {""token"": ""Turicibacter"", ""start_span"": 85, ""end_span"": 97, ""type"": ""Organism/Species""}, {""token"": ""Pedobacter"", ""start_span"": 99, ""end_span"": 109, ""type"": ""Organism/Species""}, {""token"": ""Vasilyevaea"", ""start_span"": 114, ""end_span"": 125, ""type"": ""Organism/Species""}, {""token"": ""baboon"", ""start_span"": 146, ""end_span"": 152, ""type"": ""Organism/Species""}, {""token"": ""Acinetobacter"", ""start_span"": 171, ""end_span"": 184, ""type"": ""Organism/Species""}, {""token"": ""Paenibacillus"", ""start_span"": 186, ""end_span"": 199, ""type"": ""Organism/Species""}, {""token"": ""Arthrobacter"", ""start_span"": 201, ""end_span"": 213, ""type"": ""Organism/Species""}, {""token"": ""Pectobacterium"", ""start_span"": 215, ""end_span"": 229, ""type"": ""Organism/Species""}, {""token"": ""Desemzia"", ""start_span"": 231, ""end_span"": 239, ""type"": ""Organism/Species""}, {""token"": ""Pseudomonas"", ""start_span"": 244, ""end_span"": 255, ""type"": ""Organism/Species""}, {""token"": ""baboon"", ""start_span"": 276, ""end_span"": 282, ""type"": ""Organism/Species""}, {""token"": ""human"", ""start_span"": 354, ""end_span"": 359, ""type"": ""Organism/Species""}]"
One patient had dermatomyositis - related UIP pattern, and the remaining 34 with UIP pattern were diagnosed as having IPF ( 15. 6% of 218 patients ). Table 1Characteristics of patients treated with chemotherapy and / or molecular targeted therapyNon - ILD ( n = 165) ILDAll ILD ( n = 53) P ( vs. non - ILD) IPF ( n = 34) P ( vs. non - ILD) Age, years ( range) 66 ( 30 – 91) 71 ( 57 – 86) 0. 0002770 ( 57 – 86) 0. 0053Sex Male95 ( 58 %) 51 ( 96 %)< 0. 000134 ( 100 %)< 0. 0001 Female70 ( 42 %) 2 ( 4 %) 0 ( 0 %) Smoking status Never56 ( 34 %) 2 ( 4 %)< 0. 00010 ( 0 %)< 0. 0001 Ever109 ( 66 %) 51 ( 96 %) 34 ( 100 %) Pack - year, average523467PS 0 – 1134 ( 81 %) 43 ( 81 %) 1. 000027 ( 79 %) 0. 8123 2 – 431 ( 19 %) 10 ( 19 %) 7 ( 21 %) Histology Adeno129 ( 78 %) 21 ( 40 %)< 0. 000112 ( 35 %)< 0. 0001 Squamous22 ( 13 %) 19 ( 36 %) 0. 000512 ( 35 %) 0. 0046 Adenosquamous122 Large121 Non - small1297Stage IIIB1460. 585431. 0000 IV1514731EGFR mutation Yes53 ( 32 %) 1 ( 2 %)< 0. 00010 ( 0 %)< 0. 0001 No112 ( 68 %) 52 ( 98 %) 34 ( 100 %) ILD interstitial lung disease, IPF idiopathic pulmonary fibrosis, PS performance status, EGFR epidermal growth factor receptor	"dermatomyositis	16	31	Disease/Disorder"	"UIP	42	45	Disease/Disorder"	"UIP	81	84	Disease/Disorder"	"IPF	118	121	Disease/Disorder"	"ILD	252	255	Disease/Disorder"	"ILD	267	270	Disease/Disorder"	"ILD	274	277	Disease/Disorder"	"IPF	307	310	Disease/Disorder"	"ILD	335	338	Disease/Disorder"	"ILD	1037	1040	Disease/Disorder"	"interstitial lung disease	1041	1066	Disease/Disorder"	"IPF	1068	1071	Disease/Disorder"	"idiopathic pulmonary fibrosis	1072	1101	Disease/Disorder"	"EGFR	1126	1130	Gene/Protein"	"epidermal growth factor receptor	1131	1163	Gene/Protein"	"[{""token"": ""dermatomyositis"", ""start_span"": 16, ""end_span"": 31, ""type"": ""Disease/Disorder""}, {""token"": ""UIP"", ""start_span"": 42, ""end_span"": 45, ""type"": ""Disease/Disorder""}, {""token"": ""UIP"", ""start_span"": 81, ""end_span"": 84, ""type"": ""Disease/Disorder""}, {""token"": ""IPF"", ""start_span"": 118, ""end_span"": 121, ""type"": ""Disease/Disorder""}, {""token"": ""ILD"", ""start_span"": 252, ""end_span"": 255, ""type"": ""Disease/Disorder""}, {""token"": ""ILD"", ""start_span"": 267, ""end_span"": 270, ""type"": ""Disease/Disorder""}, {""token"": ""ILD"", ""start_span"": 274, ""end_span"": 277, ""type"": ""Disease/Disorder""}, {""token"": ""IPF"", ""start_span"": 307, ""end_span"": 310, ""type"": ""Disease/Disorder""}, {""token"": ""ILD"", ""start_span"": 335, ""end_span"": 338, ""type"": ""Disease/Disorder""}, {""token"": ""ILD"", ""start_span"": 1037, ""end_span"": 1040, ""type"": ""Disease/Disorder""}, {""token"": ""interstitial lung disease"", ""start_span"": 1041, ""end_span"": 1066, ""type"": ""Disease/Disorder""}, {""token"": ""IPF"", ""start_span"": 1068, ""end_span"": 1071, ""type"": ""Disease/Disorder""}, {""token"": ""idiopathic pulmonary fibrosis"", ""start_span"": 1072, ""end_span"": 1101, ""type"": ""Disease/Disorder""}, {""token"": ""EGFR"", ""start_span"": 1126, ""end_span"": 1130, ""type"": ""Gene/Protein""}, {""token"": ""epidermal growth factor receptor"", ""start_span"": 1131, ""end_span"": 1163, ""type"": ""Gene/Protein""}]"
Multivariate analysis by Cox proportional hazards model showed that poor PS, absence of EGFR mutation, and presence of IPF were identified as poor prognostic factors for PFS and OS. Table 3Risk factors associated with PFS and OS n PFSOSMedian ( days) Univariate analysisMultivariate analysisMedian ( days) Univariate analysisMultivariate analysis P valueHR ( 95% CI) P value P valueHR ( 95% CI) P valueAgeOlder (≥ 75 years) 561500. 08271. 33 ( 0. 94 – 1. 88) 0. 10823140. 01451. 46 ( 1. 00 – 2. 15) 0. 0528Younger (< 75 years) 162186539Sex Female722280. 04031. 05 ( 0. 67 – 1. 67) 0. 82476380. 00300. 81 ( 0. 48 – 1. 36) 0. 4219 Male146149398Smoking status Never582370. 04050. 84 ( 0. 52 – 1. 33) 0. 45366100. 02420. 95 ( 0. 57 – 1. 61) 0. 8595 Ever160149430PS 0 – 1178202 < 0. 00010. 35 ( 0. 24 – 0. 52 )< 0. 0001538 < 0. 00010. 24 ( 0. 16 – 0. 36 )< 0. 0001 2 – 44079139Histology Adeno1501900. 04301. 02 ( 0. 71 – 1. 47) 0. 89545390. 00091. 00 ( 0. 67 – 1. 49) 0. 9929 Others68150283Stage IIIB201850. 72030. 78 ( 0. 47 – 1. 28) 0. 32464950. 94070. 90 ( 0. 52 – 1. 56) 0. 7136 IV198180471EGFR mutation Yes543040. 00030. 55 ( 0. 37 – 0. 82) 0. 00377710. 00010. 51 ( 0. 33 – 0. 81) 0. 0042 No164149360ILD IPF34920. 000021. 98 ( 1. 26 – 3. 11) 0. 00302230. 00021. 74 ( 1. 03 – 2. 92) 0. 0373 Non - ILD165196539 PFS progression - free survival, OS overall survival, HR hazard ratio, PS performance status, EGFR epidermal growth factor receptor, ILD interstitial lung disease, IPF idiopathic pulmonary fibrosisTable 4Associations between chemotherapeutic regimens and acute exacerbation of ILD and IPFILDIPF n AE (−) AE (+) Incidence (%) P value n AE (−) AE (+) Incidence (%) P valueDocetaxel Containing3831718. 40. 04722419520. 80. 0802 Not containing585535. 2292813. 4Pemetrexed Containing1513213. 30. 653187112. 51. 0000 Not containing817389. 94540511. 1Paclitaxel / nab - paclitaxel Containing121200. 00. 35335500. 01. 0000 Not containing84741011. 94842612. 5 ILD interstitial lung disease, IPF idiopathic pulmonary fibrosis, AE acute exacerbation	"EGFR	88	92	Gene/Protein"	"IPF	119	122	Disease/Disorder"	"Never582370	657	668	Chemical/Drug"	"EGFR	1089	1093	Gene/Protein"	"epidermal growth factor receptor	1408	1440	Gene/Protein"	"ILD	1442	1445	Disease/Disorder"	"interstitial lung disease	1446	1471	Disease/Disorder"	"IPF	1473	1476	Disease/Disorder"	"ILD	1586	1589	Disease/Disorder"	"nab	1866	1869	Chemical/Drug"	"paclitaxel	1872	1882	Chemical/Drug"	"ILD	1960	1963	Disease/Disorder"	"interstitial lung disease	1964	1989	Disease/Disorder"	"IPF	1991	1994	Disease/Disorder"	"idiopathic pulmonary fibrosis	1995	2024	Disease/Disorder"	"[{""token"": ""EGFR"", ""start_span"": 88, ""end_span"": 92, ""type"": ""Gene/Protein""}, {""token"": ""IPF"", ""start_span"": 119, ""end_span"": 122, ""type"": ""Disease/Disorder""}, {""token"": ""Never582370"", ""start_span"": 657, ""end_span"": 668, ""type"": ""Chemical/Drug""}, {""token"": ""EGFR"", ""start_span"": 1089, ""end_span"": 1093, ""type"": ""Gene/Protein""}, {""token"": ""epidermal growth factor receptor"", ""start_span"": 1408, ""end_span"": 1440, ""type"": ""Gene/Protein""}, {""token"": ""ILD"", ""start_span"": 1442, ""end_span"": 1445, ""type"": ""Disease/Disorder""}, {""token"": ""interstitial lung disease"", ""start_span"": 1446, ""end_span"": 1471, ""type"": ""Disease/Disorder""}, {""token"": ""IPF"", ""start_span"": 1473, ""end_span"": 1476, ""type"": ""Disease/Disorder""}, {""token"": ""ILD"", ""start_span"": 1586, ""end_span"": 1589, ""type"": ""Disease/Disorder""}, {""token"": ""nab"", ""start_span"": 1866, ""end_span"": 1869, ""type"": ""Chemical/Drug""}, {""token"": ""paclitaxel"", ""start_span"": 1872, ""end_span"": 1882, ""type"": ""Chemical/Drug""}, {""token"": ""ILD"", ""start_span"": 1960, ""end_span"": 1963, ""type"": ""Disease/Disorder""}, {""token"": ""interstitial lung disease"", ""start_span"": 1964, ""end_span"": 1989, ""type"": ""Disease/Disorder""}, {""token"": ""IPF"", ""start_span"": 1991, ""end_span"": 1994, ""type"": ""Disease/Disorder""}, {""token"": ""idiopathic pulmonary fibrosis"", ""start_span"": 1995, ""end_span"": 2024, ""type"": ""Disease/Disorder""}]"
In the present study, we demonstrated that ( 1) characteristics of ILD / IPF patients differed significantly from those of non - ILD patients; in particular, no IPF patients had EGFR mutation - positive tumors; ( 2) the presence of either IPF or ILD was associated with shorter PFS and OS in patients with advanced NSCLC who received chemotherapy; ( 3) DCR was significantly lower in ILD and IPF patients than in non - ILD patients, even those with EGFR - WT; and ( 4) AEs of ILD occurred more frequently after docetaxel - containing regimens than after other regimens.	"ILD	67	70	Disease/Disorder"	"IPF	73	76	Disease/Disorder"	"ILD	129	132	Disease/Disorder"	"IPF	161	164	Disease/Disorder"	"EGFR	178	182	Gene/Protein"	"tumors	203	209	Disease/Disorder"	"IPF	239	242	Disease/Disorder"	"ILD	246	249	Disease/Disorder"	"NSCLC	315	320	Disease/Disorder"	"ILD	384	387	Disease/Disorder"	"IPF	392	395	Disease/Disorder"	"ILD	419	422	Disease/Disorder"	"EGFR	449	453	Gene/Protein"	"ILD	476	479	Disease/Disorder"	"docetaxel	511	520	Chemical/Drug"	"[{""token"": ""ILD"", ""start_span"": 67, ""end_span"": 70, ""type"": ""Disease/Disorder""}, {""token"": ""IPF"", ""start_span"": 73, ""end_span"": 76, ""type"": ""Disease/Disorder""}, {""token"": ""ILD"", ""start_span"": 129, ""end_span"": 132, ""type"": ""Disease/Disorder""}, {""token"": ""IPF"", ""start_span"": 161, ""end_span"": 164, ""type"": ""Disease/Disorder""}, {""token"": ""EGFR"", ""start_span"": 178, ""end_span"": 182, ""type"": ""Gene/Protein""}, {""token"": ""tumors"", ""start_span"": 203, ""end_span"": 209, ""type"": ""Disease/Disorder""}, {""token"": ""IPF"", ""start_span"": 239, ""end_span"": 242, ""type"": ""Disease/Disorder""}, {""token"": ""ILD"", ""start_span"": 246, ""end_span"": 249, ""type"": ""Disease/Disorder""}, {""token"": ""NSCLC"", ""start_span"": 315, ""end_span"": 320, ""type"": ""Disease/Disorder""}, {""token"": ""ILD"", ""start_span"": 384, ""end_span"": 387, ""type"": ""Disease/Disorder""}, {""token"": ""IPF"", ""start_span"": 392, ""end_span"": 395, ""type"": ""Disease/Disorder""}, {""token"": ""ILD"", ""start_span"": 419, ""end_span"": 422, ""type"": ""Disease/Disorder""}, {""token"": ""EGFR"", ""start_span"": 449, ""end_span"": 453, ""type"": ""Gene/Protein""}, {""token"": ""ILD"", ""start_span"": 476, ""end_span"": 479, ""type"": ""Disease/Disorder""}, {""token"": ""docetaxel"", ""start_span"": 511, ""end_span"": 520, ""type"": ""Chemical/Drug""}]"
All experimental procedures were approved by the Northeast Ohio Medical University Institutional Animal Care and Use Committee. Fig. 1Coverage of cholera toxin - B ( CTB) transport in the superior colliculus ( SC ). a – c Whole mount brain ( cortex removed) of three mice demonstrating varying degrees of anterograde transport to major retinal targets that include lateral geniculate nucleus ( LGN ), pretectum ( PT ), and SC. a Colliculi taken from a 12 - month - old D2G control mouse show intact axonal transport with full CTB coverage in both right and left SC. b Colliculi taken from a 14 - month - old DBA / 2J mouse show compromised transport; left SC has 56% CTB coverage, right SC has 18% CTB coverage. c Colliculi taken from 12 - month - old DBA / 2J mouse demonstrate both complete CTB dropout ( left SC, 0% CTB) and complete CTB coverage ( right SC, 100% CTB ). Dotted lines indicate delineation used for microdissections of CTB - negative ( i. e ., transport absent) areas. d, e Whole mount retinas with successful CTB uptake via intravitreal injection. f Whole mount SC with areas of transport loss, corresponding to retinas in d and e.	"cholera toxin - B	146	163	Gene/Protein"	"CTB	166	169	Gene/Protein"	"mice	267	271	Organism/Species"	"mouse	481	486	Organism/Species"	"CTB	526	529	Gene/Protein"	"DBA / 2J mouse	608	622	Organism/Species"	"CTB	667	670	Gene/Protein"	"CTB	698	701	Gene/Protein"	"DBA / 2J mouse	752	766	Organism/Species"	"CTB	793	796	Gene/Protein"	"CTB	819	822	Gene/Protein"	"CTB	837	840	Gene/Protein"	"CTB	867	870	Gene/Protein"	"CTB	937	940	Gene/Protein"	"CTB	1028	1031	Gene/Protein"	"[{""token"": ""cholera toxin - B"", ""start_span"": 146, ""end_span"": 163, ""type"": ""Gene/Protein""}, {""token"": ""CTB"", ""start_span"": 166, ""end_span"": 169, ""type"": ""Gene/Protein""}, {""token"": ""mice"", ""start_span"": 267, ""end_span"": 271, ""type"": ""Organism/Species""}, {""token"": ""mouse"", ""start_span"": 481, ""end_span"": 486, ""type"": ""Organism/Species""}, {""token"": ""CTB"", ""start_span"": 526, ""end_span"": 529, ""type"": ""Gene/Protein""}, {""token"": ""DBA / 2J mouse"", ""start_span"": 608, ""end_span"": 622, ""type"": ""Organism/Species""}, {""token"": ""CTB"", ""start_span"": 667, ""end_span"": 670, ""type"": ""Gene/Protein""}, {""token"": ""CTB"", ""start_span"": 698, ""end_span"": 701, ""type"": ""Gene/Protein""}, {""token"": ""DBA / 2J mouse"", ""start_span"": 752, ""end_span"": 766, ""type"": ""Organism/Species""}, {""token"": ""CTB"", ""start_span"": 793, ""end_span"": 796, ""type"": ""Gene/Protein""}, {""token"": ""CTB"", ""start_span"": 819, ""end_span"": 822, ""type"": ""Gene/Protein""}, {""token"": ""CTB"", ""start_span"": 837, ""end_span"": 840, ""type"": ""Gene/Protein""}, {""token"": ""CTB"", ""start_span"": 867, ""end_span"": 870, ""type"": ""Gene/Protein""}, {""token"": ""CTB"", ""start_span"": 937, ""end_span"": 940, ""type"": ""Gene/Protein""}, {""token"": ""CTB"", ""start_span"": 1028, ""end_span"": 1031, ""type"": ""Gene/Protein""}]"
Group I included deaths attributed to communicable diseases and maternal, perinatal and nutritional conditions ( CD ): intestinal infectious diseases, tuberculosis ( TB ), other bacterial diseases, rabies, measles, viral hepatitis, human immunodeficiency virus ( HIV ), malaria, nutritional deficiencies, meningitis, otitis, conditions related to or aggravated by the pregnancy, childbirth or by the puerperium ( maternal causes or obstetric causes) and certain conditions originating in the perinatal period.	"communicable diseases	38	59	Disease/Disorder"	"CD	113	115	Chemical/Drug"	"intestinal infectious diseases	119	149	Disease/Disorder"	"tuberculosis	151	163	Disease/Disorder"	"TB	166	168	Disease/Disorder"	"bacterial diseases	178	196	Disease/Disorder"	"rabies	198	204	Disease/Disorder"	"measles	206	213	Disease/Disorder"	"viral hepatitis	215	230	Disease/Disorder"	"human immunodeficiency virus	232	260	Organism/Species"	"HIV	263	266	Organism/Species"	"malaria	270	277	Disease/Disorder"	"nutritional deficiencies	279	303	Disease/Disorder"	"meningitis	305	315	Disease/Disorder"	"otitis	317	323	Disease/Disorder"	"[{""token"": ""communicable diseases"", ""start_span"": 38, ""end_span"": 59, ""type"": ""Disease/Disorder""}, {""token"": ""CD"", ""start_span"": 113, ""end_span"": 115, ""type"": ""Chemical/Drug""}, {""token"": ""intestinal infectious diseases"", ""start_span"": 119, ""end_span"": 149, ""type"": ""Disease/Disorder""}, {""token"": ""tuberculosis"", ""start_span"": 151, ""end_span"": 163, ""type"": ""Disease/Disorder""}, {""token"": ""TB"", ""start_span"": 166, ""end_span"": 168, ""type"": ""Disease/Disorder""}, {""token"": ""bacterial diseases"", ""start_span"": 178, ""end_span"": 196, ""type"": ""Disease/Disorder""}, {""token"": ""rabies"", ""start_span"": 198, ""end_span"": 204, ""type"": ""Disease/Disorder""}, {""token"": ""measles"", ""start_span"": 206, ""end_span"": 213, ""type"": ""Disease/Disorder""}, {""token"": ""viral hepatitis"", ""start_span"": 215, ""end_span"": 230, ""type"": ""Disease/Disorder""}, {""token"": ""human immunodeficiency virus"", ""start_span"": 232, ""end_span"": 260, ""type"": ""Organism/Species""}, {""token"": ""HIV"", ""start_span"": 263, ""end_span"": 266, ""type"": ""Organism/Species""}, {""token"": ""malaria"", ""start_span"": 270, ""end_span"": 277, ""type"": ""Disease/Disorder""}, {""token"": ""nutritional deficiencies"", ""start_span"": 279, ""end_span"": 303, ""type"": ""Disease/Disorder""}, {""token"": ""meningitis"", ""start_span"": 305, ""end_span"": 315, ""type"": ""Disease/Disorder""}, {""token"": ""otitis"", ""start_span"": 317, ""end_span"": 323, ""type"": ""Disease/Disorder""}]"
Fourteen TFs were present in the network ( MZF1, SF1, SMAD4, TEF, HBP1, MSX2, NF1, SIX3, DLX2, LEF1, NFAT5, HLF, IRX2 and KLF6 ), none of which displayed DE, but collectively linked 108 piebald - associated genes.	"TFs	9	12	Gene/Protein"	"MZF1	43	47	Gene/Protein"	"SF1	49	52	Gene/Protein"	"SMAD4	54	59	Gene/Protein"	"TEF	61	64	Gene/Protein"	"HBP1	66	70	Gene/Protein"	"MSX2	72	76	Gene/Protein"	"NF1	78	81	Gene/Protein"	"SIX3	83	87	Gene/Protein"	"DLX2	89	93	Gene/Protein"	"LEF1	95	99	Gene/Protein"	"NFAT5	101	106	Gene/Protein"	"HLF	108	111	Gene/Protein"	"IRX2	113	117	Gene/Protein"	"KLF6	122	126	Gene/Protein"	"[{""token"": ""TFs"", ""start_span"": 9, ""end_span"": 12, ""type"": ""Gene/Protein""}, {""token"": ""MZF1"", ""start_span"": 43, ""end_span"": 47, ""type"": ""Gene/Protein""}, {""token"": ""SF1"", ""start_span"": 49, ""end_span"": 52, ""type"": ""Gene/Protein""}, {""token"": ""SMAD4"", ""start_span"": 54, ""end_span"": 59, ""type"": ""Gene/Protein""}, {""token"": ""TEF"", ""start_span"": 61, ""end_span"": 64, ""type"": ""Gene/Protein""}, {""token"": ""HBP1"", ""start_span"": 66, ""end_span"": 70, ""type"": ""Gene/Protein""}, {""token"": ""MSX2"", ""start_span"": 72, ""end_span"": 76, ""type"": ""Gene/Protein""}, {""token"": ""NF1"", ""start_span"": 78, ""end_span"": 81, ""type"": ""Gene/Protein""}, {""token"": ""SIX3"", ""start_span"": 83, ""end_span"": 87, ""type"": ""Gene/Protein""}, {""token"": ""DLX2"", ""start_span"": 89, ""end_span"": 93, ""type"": ""Gene/Protein""}, {""token"": ""LEF1"", ""start_span"": 95, ""end_span"": 99, ""type"": ""Gene/Protein""}, {""token"": ""NFAT5"", ""start_span"": 101, ""end_span"": 106, ""type"": ""Gene/Protein""}, {""token"": ""HLF"", ""start_span"": 108, ""end_span"": 111, ""type"": ""Gene/Protein""}, {""token"": ""IRX2"", ""start_span"": 113, ""end_span"": 117, ""type"": ""Gene/Protein""}, {""token"": ""KLF6"", ""start_span"": 122, ""end_span"": 126, ""type"": ""Gene/Protein""}]"
Among catfishes, hearing abilities were measured in representatives of 11 out of 36 families: in doradids, pimelodids ( long - whiskered catfishes ), callichthyids, ariids, pseudopimelodids, malapterurids, heptapterids, mochokids, auchenipterids, silurids ( sheatfishes) and ictalurids ( North American freshwater catfishes) [ 19 ], [ 32 ]–[ 38 ].	"catfishes	6	15	Organism/Species"	"doradids	97	105	Organism/Species"	"pimelodids	107	117	Organism/Species"	"long - whiskered catfishes	120	146	Organism/Species"	"callichthyids	150	163	Organism/Species"	"ariids	165	171	Organism/Species"	"pseudopimelodids	173	189	Organism/Species"	"malapterurids	191	204	Organism/Species"	"heptapterids	206	218	Organism/Species"	"mochokids	220	229	Organism/Species"	"auchenipterids	231	245	Organism/Species"	"silurids	247	255	Organism/Species"	"sheatfishes	258	269	Organism/Species"	"ictalurids	275	285	Organism/Species"	"North American freshwater catfishes	288	323	Organism/Species"	"[{""token"": ""catfishes"", ""start_span"": 6, ""end_span"": 15, ""type"": ""Organism/Species""}, {""token"": ""doradids"", ""start_span"": 97, ""end_span"": 105, ""type"": ""Organism/Species""}, {""token"": ""pimelodids"", ""start_span"": 107, ""end_span"": 117, ""type"": ""Organism/Species""}, {""token"": ""long - whiskered catfishes"", ""start_span"": 120, ""end_span"": 146, ""type"": ""Organism/Species""}, {""token"": ""callichthyids"", ""start_span"": 150, ""end_span"": 163, ""type"": ""Organism/Species""}, {""token"": ""ariids"", ""start_span"": 165, ""end_span"": 171, ""type"": ""Organism/Species""}, {""token"": ""pseudopimelodids"", ""start_span"": 173, ""end_span"": 189, ""type"": ""Organism/Species""}, {""token"": ""malapterurids"", ""start_span"": 191, ""end_span"": 204, ""type"": ""Organism/Species""}, {""token"": ""heptapterids"", ""start_span"": 206, ""end_span"": 218, ""type"": ""Organism/Species""}, {""token"": ""mochokids"", ""start_span"": 220, ""end_span"": 229, ""type"": ""Organism/Species""}, {""token"": ""auchenipterids"", ""start_span"": 231, ""end_span"": 245, ""type"": ""Organism/Species""}, {""token"": ""silurids"", ""start_span"": 247, ""end_span"": 255, ""type"": ""Organism/Species""}, {""token"": ""sheatfishes"", ""start_span"": 258, ""end_span"": 269, ""type"": ""Organism/Species""}, {""token"": ""ictalurids"", ""start_span"": 275, ""end_span"": 285, ""type"": ""Organism/Species""}, {""token"": ""North American freshwater catfishes"", ""start_span"": 288, ""end_span"": 323, ""type"": ""Organism/Species""}]"
Fungi used in the study are described below, along with the strains examined ( synonymous strain identifiers in parentheses ), host organisms and geographical location of origin8. Fusarium verticillioides ( teleomorph Gibberella moniliformis ), sequenced strain FGSC 7600 ( JFL A00149 / FRC M3125 / NRRL 20956 ), maize, California, USA55; strain JFL A00999 ( FGSC 7603 / ATCC 201261 / FRC M3703 / NRRL 20984 ), maize, Indiana, USA; strain MRC 826 ( FRC M1325 / NRRL 13447 ), maize, South Africa. Fusarium graminearum ( teleomorph Gibberella zeae ), sequenced strain PH - 1 ( NRRL 31084 / ATCC MYA - 4620 / FGSC 9075 ), wheat, Michigan, USA56. Fusarium oxysporum f. sp. lycopersici, sequenced strain FOL 4287 ( NRRL 34936 / CBS 123668 / FGSC 9935 ), tomato, Spain55. Aspergillus flavus, sequenced strain NRRL 3357 ( ATCC 200026 / FGSC A1120 / JCM 12722 / SRRC 167 ), maize and peanut, USA57. Aspergillus nidulans ( teleomorph Emericella nidulans ), sequenced strain FGSC A4 ( ATCC 38163 / CBS 112. 46 / NRRL 194 / M139 ), Glasgow soil sample58.	"Fungi	0	5	Organism/Species"	"Fusarium verticillioides	180	204	Organism/Species"	"Gibberella moniliformis	218	241	Organism/Species"	"maize	313	318	Organism/Species"	"maize	411	416	Organism/Species"	"maize	475	480	Organism/Species"	"Fusarium graminearum	496	516	Organism/Species"	"Gibberella zeae	530	545	Organism/Species"	"wheat	619	624	Organism/Species"	"tomato	749	755	Organism/Species"	"Aspergillus	766	777	Organism/Species"	"maize	866	871	Organism/Species"	"peanut	876	882	Organism/Species"	"Aspergillus nidulans	891	911	Organism/Species"	"Emericella nidulans	925	944	Organism/Species"	"[{""token"": ""Fungi"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Organism/Species""}, {""token"": ""Fusarium verticillioides"", ""start_span"": 180, ""end_span"": 204, ""type"": ""Organism/Species""}, {""token"": ""Gibberella moniliformis"", ""start_span"": 218, ""end_span"": 241, ""type"": ""Organism/Species""}, {""token"": ""maize"", ""start_span"": 313, ""end_span"": 318, ""type"": ""Organism/Species""}, {""token"": ""maize"", ""start_span"": 411, ""end_span"": 416, ""type"": ""Organism/Species""}, {""token"": ""maize"", ""start_span"": 475, ""end_span"": 480, ""type"": ""Organism/Species""}, {""token"": ""Fusarium graminearum"", ""start_span"": 496, ""end_span"": 516, ""type"": ""Organism/Species""}, {""token"": ""Gibberella zeae"", ""start_span"": 530, ""end_span"": 545, ""type"": ""Organism/Species""}, {""token"": ""wheat"", ""start_span"": 619, ""end_span"": 624, ""type"": ""Organism/Species""}, {""token"": ""tomato"", ""start_span"": 749, ""end_span"": 755, ""type"": ""Organism/Species""}, {""token"": ""Aspergillus"", ""start_span"": 766, ""end_span"": 777, ""type"": ""Organism/Species""}, {""token"": ""maize"", ""start_span"": 866, ""end_span"": 871, ""type"": ""Organism/Species""}, {""token"": ""peanut"", ""start_span"": 876, ""end_span"": 882, ""type"": ""Organism/Species""}, {""token"": ""Aspergillus nidulans"", ""start_span"": 891, ""end_span"": 911, ""type"": ""Organism/Species""}, {""token"": ""Emericella nidulans"", ""start_span"": 925, ""end_span"": 944, ""type"": ""Organism/Species""}]"
Irradiation of Ptc1 +/- ( Ptc1 +/-) or Rad54 -/- mice ( Rad54 -/-/ Ptc1 +/-) caused significantly increase MB incidence compared with unirradiated mice, both in wt Parp - 1 background [ Ptc1 +/- ( 82% vs 14 %; P = 0. 0001 ); Rad54 -/-/ Ptc1 +/- ( 84% vs 15 %; P = 0. 0001 )] and in Parp - 1 heterozygotes ( Parp - 1 +/-/ Ptc1 +/- 56% vs 30 %; P = 0. 0447) ( Figure 1D - 1F ).	"Ptc1	15	19	Gene/Protein"	"Ptc1	26	30	Gene/Protein"	"Rad54	39	44	Gene/Protein"	"mice	49	53	Organism/Species"	"Rad54	56	61	Gene/Protein"	"Ptc1	67	71	Gene/Protein"	"MB	107	109	Disease/Disorder"	"mice	147	151	Organism/Species"	"Parp - 1	164	172	Gene/Protein"	"Ptc1	186	190	Gene/Protein"	"Rad54	225	230	Gene/Protein"	"Ptc1	236	240	Gene/Protein"	"Parp - 1	282	290	Gene/Protein"	"Parp - 1	307	315	Gene/Protein"	"Ptc1	321	325	Gene/Protein"	"[{""token"": ""Ptc1"", ""start_span"": 15, ""end_span"": 19, ""type"": ""Gene/Protein""}, {""token"": ""Ptc1"", ""start_span"": 26, ""end_span"": 30, ""type"": ""Gene/Protein""}, {""token"": ""Rad54"", ""start_span"": 39, ""end_span"": 44, ""type"": ""Gene/Protein""}, {""token"": ""mice"", ""start_span"": 49, ""end_span"": 53, ""type"": ""Organism/Species""}, {""token"": ""Rad54"", ""start_span"": 56, ""end_span"": 61, ""type"": ""Gene/Protein""}, {""token"": ""Ptc1"", ""start_span"": 67, ""end_span"": 71, ""type"": ""Gene/Protein""}, {""token"": ""MB"", ""start_span"": 107, ""end_span"": 109, ""type"": ""Disease/Disorder""}, {""token"": ""mice"", ""start_span"": 147, ""end_span"": 151, ""type"": ""Organism/Species""}, {""token"": ""Parp - 1"", ""start_span"": 164, ""end_span"": 172, ""type"": ""Gene/Protein""}, {""token"": ""Ptc1"", ""start_span"": 186, ""end_span"": 190, ""type"": ""Gene/Protein""}, {""token"": ""Rad54"", ""start_span"": 225, ""end_span"": 230, ""type"": ""Gene/Protein""}, {""token"": ""Ptc1"", ""start_span"": 236, ""end_span"": 240, ""type"": ""Gene/Protein""}, {""token"": ""Parp - 1"", ""start_span"": 282, ""end_span"": 290, ""type"": ""Gene/Protein""}, {""token"": ""Parp - 1"", ""start_span"": 307, ""end_span"": 315, ""type"": ""Gene/Protein""}, {""token"": ""Ptc1"", ""start_span"": 321, ""end_span"": 325, ""type"": ""Gene/Protein""}]"
( A) Effect of gamma - irradiation ( γ - IR, 1 Gy ), methotrexate ( MTX, 0. 01 μg / ml ), cytarabine ( ARAC, 0. 025 μg / ml) on growth of MLL - Scr and MLL - KD cell lines over two days; ( B) Percentage of dying or necrotic cells ( normalized to untreated) in MLL - Scr and MLL - KD after 48 hours in the presence of dexamethasone ( DEX, 250 μM or 500 μM) or following gamma - irradiation ( γ - IR, 1 Gy ); ( C) Ratio of lactate production / glucose consumption over two days in MLL - Scr and MLL - KD cells; ( D) Relative expression of GILZ mRNA as measured by qRT - PCR in MLL - Scr and MLL - KD cell lines incubated for four hours in the absence (-) or presence (+) of dexamethasone ( 1 μM ); In each case ( A - D) data represent mean ± SEM from 3 - 6 independent experiments with statistical analysis by unpaired t - test; * p < 0. 05, ** p < 0. 01.	"methotrexate	53	65	Chemical/Drug"	"cytarabine	90	100	Chemical/Drug"	"MLL	138	141	Gene/Protein"	"MLL	152	155	Gene/Protein"	"MLL	260	263	Gene/Protein"	"MLL	274	277	Gene/Protein"	"dexamethasone	317	330	Chemical/Drug"	"lactate	421	428	Chemical/Drug"	"glucose	442	449	Chemical/Drug"	"MLL	479	482	Gene/Protein"	"MLL	493	496	Gene/Protein"	"GILZ	537	541	Gene/Protein"	"MLL	575	578	Gene/Protein"	"MLL	589	592	Gene/Protein"	"dexamethasone	672	685	Chemical/Drug"	"[{""token"": ""methotrexate"", ""start_span"": 53, ""end_span"": 65, ""type"": ""Chemical/Drug""}, {""token"": ""cytarabine"", ""start_span"": 90, ""end_span"": 100, ""type"": ""Chemical/Drug""}, {""token"": ""MLL"", ""start_span"": 138, ""end_span"": 141, ""type"": ""Gene/Protein""}, {""token"": ""MLL"", ""start_span"": 152, ""end_span"": 155, ""type"": ""Gene/Protein""}, {""token"": ""MLL"", ""start_span"": 260, ""end_span"": 263, ""type"": ""Gene/Protein""}, {""token"": ""MLL"", ""start_span"": 274, ""end_span"": 277, ""type"": ""Gene/Protein""}, {""token"": ""dexamethasone"", ""start_span"": 317, ""end_span"": 330, ""type"": ""Chemical/Drug""}, {""token"": ""lactate"", ""start_span"": 421, ""end_span"": 428, ""type"": ""Chemical/Drug""}, {""token"": ""glucose"", ""start_span"": 442, ""end_span"": 449, ""type"": ""Chemical/Drug""}, {""token"": ""MLL"", ""start_span"": 479, ""end_span"": 482, ""type"": ""Gene/Protein""}, {""token"": ""MLL"", ""start_span"": 493, ""end_span"": 496, ""type"": ""Gene/Protein""}, {""token"": ""GILZ"", ""start_span"": 537, ""end_span"": 541, ""type"": ""Gene/Protein""}, {""token"": ""MLL"", ""start_span"": 575, ""end_span"": 578, ""type"": ""Gene/Protein""}, {""token"": ""MLL"", ""start_span"": 589, ""end_span"": 592, ""type"": ""Gene/Protein""}, {""token"": ""dexamethasone"", ""start_span"": 672, ""end_span"": 685, ""type"": ""Chemical/Drug""}]"
Serum samples from all four time points were analysed for cytokine concentrations ( IL - 10, IL - 1β, IL - 2, IL - 4, IL - 6, IL - 8, TNFα, monocyte chemotactic protein - 1 ), as well as the vascular injury molecules C - reactive protein ( CRP ), serum amyloid A, soluble intracellular adhesion molecule ( sICAM) and soluble vascular adhesion molecule.	"cytokine	58	66	Gene/Protein"	"IL - 10	84	91	Gene/Protein"	"IL - 1β	93	100	Gene/Protein"	"IL - 2	102	108	Gene/Protein"	"IL - 4	110	116	Gene/Protein"	"IL - 6	118	124	Gene/Protein"	"IL - 8	126	132	Gene/Protein"	"TNFα	134	138	Gene/Protein"	"monocyte chemotactic protein - 1	140	172	Gene/Protein"	"C - reactive protein	217	237	Gene/Protein"	"CRP	240	243	Gene/Protein"	"serum amyloid A	247	262	Gene/Protein"	"intracellular adhesion molecule	272	303	Gene/Protein"	"sICAM	306	311	Gene/Protein"	"vascular adhesion molecule	325	351	Gene/Protein"	"[{""token"": ""cytokine"", ""start_span"": 58, ""end_span"": 66, ""type"": ""Gene/Protein""}, {""token"": ""IL - 10"", ""start_span"": 84, ""end_span"": 91, ""type"": ""Gene/Protein""}, {""token"": ""IL - 1\u03b2"", ""start_span"": 93, ""end_span"": 100, ""type"": ""Gene/Protein""}, {""token"": ""IL - 2"", ""start_span"": 102, ""end_span"": 108, ""type"": ""Gene/Protein""}, {""token"": ""IL - 4"", ""start_span"": 110, ""end_span"": 116, ""type"": ""Gene/Protein""}, {""token"": ""IL - 6"", ""start_span"": 118, ""end_span"": 124, ""type"": ""Gene/Protein""}, {""token"": ""IL - 8"", ""start_span"": 126, ""end_span"": 132, ""type"": ""Gene/Protein""}, {""token"": ""TNF\u03b1"", ""start_span"": 134, ""end_span"": 138, ""type"": ""Gene/Protein""}, {""token"": ""monocyte chemotactic protein - 1"", ""start_span"": 140, ""end_span"": 172, ""type"": ""Gene/Protein""}, {""token"": ""C - reactive protein"", ""start_span"": 217, ""end_span"": 237, ""type"": ""Gene/Protein""}, {""token"": ""CRP"", ""start_span"": 240, ""end_span"": 243, ""type"": ""Gene/Protein""}, {""token"": ""serum amyloid A"", ""start_span"": 247, ""end_span"": 262, ""type"": ""Gene/Protein""}, {""token"": ""intracellular adhesion molecule"", ""start_span"": 272, ""end_span"": 303, ""type"": ""Gene/Protein""}, {""token"": ""sICAM"", ""start_span"": 306, ""end_span"": 311, ""type"": ""Gene/Protein""}, {""token"": ""vascular adhesion molecule"", ""start_span"": 325, ""end_span"": 351, ""type"": ""Gene/Protein""}]"
Nontoxic levels of 4 - HNE have been described to modify ( i) signal transduction regulating the de novo synthesis of detoxifying enzymes ( e. g ., via transcription factor Nrf2 and the transcription - enhancer antioxidant response element ARE ); ( ii) cell proliferation ( e. g ., via c - Jun N - terminal kinase JNK ); ( iii) apoptosis and cell cycle regulation ( e. g ., via p53 ); ( iv) differentiation ( e. g ., via mitogen - activated protein kinase MAPK and growth factor receptors ); ( v) inflammatory response; ( vi) expression of the cellular adhesion molecules ICAM - 1, VCAM - 1, and E - selectin ( e. g ., via transcription factors p38 and NF - kappaB ); and ( vii) protein turnover ( via proteasome activity) [ 10, 11, 36 – 38 ].	"transcription factor	152	172	Gene/Protein"	"Nrf2	173	177	Gene/Protein"	"c - Jun N - terminal kinase	286	313	Gene/Protein"	"JNK	314	317	Gene/Protein"	"p53	378	381	Gene/Protein"	"mitogen - activated protein kinase	421	455	Gene/Protein"	"MAPK	456	460	Gene/Protein"	"growth factor receptors	465	488	Gene/Protein"	"cellular adhesion molecules	544	571	Gene/Protein"	"ICAM - 1	572	580	Gene/Protein"	"VCAM - 1	582	590	Gene/Protein"	"E - selectin	596	608	Gene/Protein"	"transcription factors	623	644	Gene/Protein"	"p38	645	648	Gene/Protein"	"NF - kappaB	653	664	Gene/Protein"	"[{""token"": ""transcription factor"", ""start_span"": 152, ""end_span"": 172, ""type"": ""Gene/Protein""}, {""token"": ""Nrf2"", ""start_span"": 173, ""end_span"": 177, ""type"": ""Gene/Protein""}, {""token"": ""c - Jun N - terminal kinase"", ""start_span"": 286, ""end_span"": 313, ""type"": ""Gene/Protein""}, {""token"": ""JNK"", ""start_span"": 314, ""end_span"": 317, ""type"": ""Gene/Protein""}, {""token"": ""p53"", ""start_span"": 378, ""end_span"": 381, ""type"": ""Gene/Protein""}, {""token"": ""mitogen - activated protein kinase"", ""start_span"": 421, ""end_span"": 455, ""type"": ""Gene/Protein""}, {""token"": ""MAPK"", ""start_span"": 456, ""end_span"": 460, ""type"": ""Gene/Protein""}, {""token"": ""growth factor receptors"", ""start_span"": 465, ""end_span"": 488, ""type"": ""Gene/Protein""}, {""token"": ""cellular adhesion molecules"", ""start_span"": 544, ""end_span"": 571, ""type"": ""Gene/Protein""}, {""token"": ""ICAM - 1"", ""start_span"": 572, ""end_span"": 580, ""type"": ""Gene/Protein""}, {""token"": ""VCAM - 1"", ""start_span"": 582, ""end_span"": 590, ""type"": ""Gene/Protein""}, {""token"": ""E - selectin"", ""start_span"": 596, ""end_span"": 608, ""type"": ""Gene/Protein""}, {""token"": ""transcription factors"", ""start_span"": 623, ""end_span"": 644, ""type"": ""Gene/Protein""}, {""token"": ""p38"", ""start_span"": 645, ""end_span"": 648, ""type"": ""Gene/Protein""}, {""token"": ""NF - kappaB"", ""start_span"": 653, ""end_span"": 664, ""type"": ""Gene/Protein""}]"
IPA, ingenuity pathway analysis; IFN, interferon; EA, European – American; AA, African - American; RBP +, anti - RNA - binding - protein ( RBP) antibody positive; RBP −, RBP antibody negative; IRF, interferon - regulatory factor; RIG1, retinoic acid - inducible gene 1; and PKR, protein kinase R.	"IFN	33	36	Gene/Protein"	"interferon	38	48	Gene/Protein"	"RBP	99	102	Gene/Protein"	"RNA - binding - protein	113	136	Gene/Protein"	"RBP	139	142	Gene/Protein"	"antibody	144	152	Gene/Protein"	"RBP	163	166	Gene/Protein"	"RBP	170	173	Gene/Protein"	"antibody	174	182	Gene/Protein"	"IRF	193	196	Gene/Protein"	"interferon - regulatory factor	198	228	Gene/Protein"	"RIG1	230	234	Gene/Protein"	"retinoic acid - inducible gene 1	236	268	Gene/Protein"	"PKR	274	277	Gene/Protein"	"protein kinase R	279	295	Gene/Protein"	"[{""token"": ""IFN"", ""start_span"": 33, ""end_span"": 36, ""type"": ""Gene/Protein""}, {""token"": ""interferon"", ""start_span"": 38, ""end_span"": 48, ""type"": ""Gene/Protein""}, {""token"": ""RBP"", ""start_span"": 99, ""end_span"": 102, ""type"": ""Gene/Protein""}, {""token"": ""RNA - binding - protein"", ""start_span"": 113, ""end_span"": 136, ""type"": ""Gene/Protein""}, {""token"": ""RBP"", ""start_span"": 139, ""end_span"": 142, ""type"": ""Gene/Protein""}, {""token"": ""antibody"", ""start_span"": 144, ""end_span"": 152, ""type"": ""Gene/Protein""}, {""token"": ""RBP"", ""start_span"": 163, ""end_span"": 166, ""type"": ""Gene/Protein""}, {""token"": ""RBP"", ""start_span"": 170, ""end_span"": 173, ""type"": ""Gene/Protein""}, {""token"": ""antibody"", ""start_span"": 174, ""end_span"": 182, ""type"": ""Gene/Protein""}, {""token"": ""IRF"", ""start_span"": 193, ""end_span"": 196, ""type"": ""Gene/Protein""}, {""token"": ""interferon - regulatory factor"", ""start_span"": 198, ""end_span"": 228, ""type"": ""Gene/Protein""}, {""token"": ""RIG1"", ""start_span"": 230, ""end_span"": 234, ""type"": ""Gene/Protein""}, {""token"": ""retinoic acid - inducible gene 1"", ""start_span"": 236, ""end_span"": 268, ""type"": ""Gene/Protein""}, {""token"": ""PKR"", ""start_span"": 274, ""end_span"": 277, ""type"": ""Gene/Protein""}, {""token"": ""protein kinase R"", ""start_span"": 279, ""end_span"": 295, ""type"": ""Gene/Protein""}]"
The canonical Wnt pathway ( or Wnt / β - catenin pathway) leads to an accumulation of β - catenin in the cytoplasm that can be translocated into the nucleus and activate transcription factors. 3 A recent analysis of human HCC has shown that the Wnt pathway is activated in 49% of HCC and that almost half of these had features consistent with the activation of the Wnt / β - catenin pathway. 6 These data are in line with an integrated analysis of somatic mutations which revealed activating mutations of β - catenin ( CTNNB1) in 33% of human HCC.	"Wnt	14	17	Gene/Protein"	"Wnt	31	34	Gene/Protein"	"β - catenin	37	48	Gene/Protein"	"β - catenin	86	97	Gene/Protein"	"transcription factors	170	191	Gene/Protein"	"human	216	221	Organism/Species"	"HCC	222	225	Disease/Disorder"	"Wnt	245	248	Gene/Protein"	"HCC	280	283	Disease/Disorder"	"Wnt	365	368	Gene/Protein"	"β - catenin	371	382	Gene/Protein"	"β - catenin	505	516	Gene/Protein"	"CTNNB1	519	525	Gene/Protein"	"human	537	542	Organism/Species"	"HCC	543	546	Disease/Disorder"	"[{""token"": ""Wnt"", ""start_span"": 14, ""end_span"": 17, ""type"": ""Gene/Protein""}, {""token"": ""Wnt"", ""start_span"": 31, ""end_span"": 34, ""type"": ""Gene/Protein""}, {""token"": ""\u03b2 - catenin"", ""start_span"": 37, ""end_span"": 48, ""type"": ""Gene/Protein""}, {""token"": ""\u03b2 - catenin"", ""start_span"": 86, ""end_span"": 97, ""type"": ""Gene/Protein""}, {""token"": ""transcription factors"", ""start_span"": 170, ""end_span"": 191, ""type"": ""Gene/Protein""}, {""token"": ""human"", ""start_span"": 216, ""end_span"": 221, ""type"": ""Organism/Species""}, {""token"": ""HCC"", ""start_span"": 222, ""end_span"": 225, ""type"": ""Disease/Disorder""}, {""token"": ""Wnt"", ""start_span"": 245, ""end_span"": 248, ""type"": ""Gene/Protein""}, {""token"": ""HCC"", ""start_span"": 280, ""end_span"": 283, ""type"": ""Disease/Disorder""}, {""token"": ""Wnt"", ""start_span"": 365, ""end_span"": 368, ""type"": ""Gene/Protein""}, {""token"": ""\u03b2 - catenin"", ""start_span"": 371, ""end_span"": 382, ""type"": ""Gene/Protein""}, {""token"": ""\u03b2 - catenin"", ""start_span"": 505, ""end_span"": 516, ""type"": ""Gene/Protein""}, {""token"": ""CTNNB1"", ""start_span"": 519, ""end_span"": 525, ""type"": ""Gene/Protein""}, {""token"": ""human"", ""start_span"": 537, ""end_span"": 542, ""type"": ""Organism/Species""}, {""token"": ""HCC"", ""start_span"": 543, ""end_span"": 546, ""type"": ""Disease/Disorder""}]"
